Treatment in Patients with Refractory ITP
Eight out of 11 studies discussed the treatment for pediatric patients
with rITP. Treatment modalities included
splenectomy9,11,
rituximab9,13,16–18, romiplostim14,
and dapsone8 (Table 2). The most frequent treatment
used in the treatment of rITP was rituximab; the reported efficacy of
rituximab in rITP was wide-ranging from
0-72%.9,13,17,18 For splenectomy, eight out of 13
patients achieved complete remission, 2 partial remission, and 3 had no
response.9,11